organization · Reporting owner
Flagship Ventures Fund IV, L.P.
Disclosed activity across 9 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | 10% owner | October 13, 2022 | October 17, 2022 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | 10% owner | July 11, 2023 | July 13, 2023 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | 10% owner | February 08, 2021 | February 10, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | 10% owner | August 17, 2020 | August 20, 2020 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | 10% owner | March 19, 2021 | March 23, 2021 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | 10% owner | November 23, 2020 | November 25, 2020 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | 10% owner | August 17, 2017 | August 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date October 13, 2022 · Filed October 17, 2022
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 14,101,638 |
Last balance in matching sequence
After 2022-10-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-10-13 · Purchase · Acquired 2,743,902 · Balance 11,344,305 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Row 2 · 2022-10-13 · Purchase · Acquired 2,757,333 · Balance 14,101,638 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities I, L.P. | 6,299,611 |
Last balance in matching sequence
After 2022-10-13 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2022-10-13 · Purchase · Acquired 914,634 · Balance 5,380,500 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Row 4 · 2022-10-13 · Purchase · Acquired 919,111 · Balance 6,299,611 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy FPA, L.P. | 3,048,780 |
Reported balance
After 2022-10-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-10-13 · Purchase · Acquired 3,048,780 · Balance 3,048,780 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 2,004,657 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,004,657 F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV, LLC | 2,035,830 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,035,830 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund 2007, L.P. | 1,761,029 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,761,029 F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Evelo Biosciences, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 1,461,795 |
Reported balance
After 2023-07-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,461,795 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 1,493,241 |
Reported balance
After 2023-07-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,493,241 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 3,931,685 |
Reported balance
After 2023-07-11 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-07-11 · Purchase · Acquired 3,246,753 · Balance 3,931,685 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 94,371 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 94,371 F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities Fund I, L.P. | 274,766 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 274,766 F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 34,219 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 34,219 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V LLC | 132,282 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 132,282 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 210,064 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 210,064 F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 80,494 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 80,494 F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Side Fund, L.P. | 39,798 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 39,798 F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Disruptive Innovation Fund, L.P. | 179,909 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 179,909 F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Kaleido Biosciences, Inc.
Report date February 08, 2021 · Filed February 10, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,685,444 |
Reported balance
After 2021-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-08 · Purchase · Acquired 71,666 · Balance 1,685,444 F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,982,639 |
Reported balance
After 2021-02-08 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 2,982,639 F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 738,333 |
Reported balance
After 2021-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 738,333 F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering. F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 42,865 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,865 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,500,000 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,500,000 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,560,096 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,560,096 F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 639,360 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 639,360 F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,560,523 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,560,523 F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 216,451 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 216,451 F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,649,999 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,649,999 F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.
F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Moderna, Inc.
Report date August 17, 2020 · Filed August 20, 2020
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV-Rx, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 14,435,589 |
Reported balance
After 2020-08-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-08-17 · Other · Disposed 7,550,810 · Balance 14,435,589 F1: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,971,576 |
Reported balance
After 2020-08-17 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-08-17 · Other · Disposed 1,449,190 · Balance 4,971,576 F1: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-08-17 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2020-08-17 · Other · Disposed 2,053,049 · Balance 0 F1: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 11,460,435 |
Reported balance
Holding disclosure · report date 2020-08-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 11,460,435 F5: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,924 |
Reported balance
Holding disclosure · report date 2020-08-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,924 F6: Shares held by Flagship Pioneering, Inc. ("Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Pioneering. Each of the reporting persons except for Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,101,703 |
Reported balance
Holding disclosure · report date 2020-08-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,101,703 F1: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F7: Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Pioneering, Inc. ("Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Pioneering. Each of the reporting persons except for Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Rubius Therapeutics, Inc.
Report date March 19, 2021 · Filed March 23, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,393,593 |
Reported balance
After 2021-03-19 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 15,393,593 F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,859,414 |
Reported balance
After 2021-03-19 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 5,859,414 F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering. F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,633,703 |
Reported balance
After 2021-03-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 2,633,703 F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering. F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,000,000 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,000,000 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,830,402 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,830,402 F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,789,414 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,789,414 F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP.
F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering.
F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering.
F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Seres Therapeutics, Inc.
Report date November 23, 2020 · Filed November 25, 2020
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV-Rx, L.P., Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Flagship Pioneering Fund VI General Partner LLC, Flagship Pioneering Fund VI, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,434,600 |
Reported balance
After 2020-11-23 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-11-23 · Other · Disposed 3,587,820 · Balance 4,434,600 F1: On November 23, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 3,587,820 shares and 642,180 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 837,782 shares and 128,452 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. received 335,171 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering and as a manager of Flagship Fund IV GP. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,283,282 |
Reported balance
After 2020-11-23 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-11-23 · Other · Disposed 642,180 · Balance 1,283,282 F1: On November 23, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 3,587,820 shares and 642,180 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 837,782 shares and 128,452 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. received 335,171 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-11-23 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2020-11-23 · Other · Disposed 966,234 · Balance 0 F1: On November 23, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 3,587,820 shares and 642,180 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 837,782 shares and 128,452 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. received 335,171 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,258,134 |
Reported balance
After 2020-11-23 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2020-11-23 · Other · Disposed 1,186,310 · Balance 3,258,134 F5: On November 23, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") distributed to its limited partners, pro rata and without consideration, 1,186,310 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan Ph.D. is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,962,963 |
Reported balance
After 2020-11-23 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2020-11-23 · Other · Disposed 1,481,481 · Balance 2,962,963 F7: On November 23, 2020, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 1,481,481 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed to its members, pro rata and without consideration, the 43,154 shares it received from Flagship Fund VI. Each of Noubar B. Afeyan, Ph.D. and a trust for the benefit of Dr. Afeyan's children received 12,853 shares through Flagship Fund VI GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F8: Shares held by Flagship Fund VI. Flagship Fund VI GP is the general partner of Flagship Fund VI. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-11-23 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2020-11-23 · Other · Disposed 43,154 · Balance 0 F7: On November 23, 2020, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 1,481,481 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed to its members, pro rata and without consideration, the 43,154 shares it received from Flagship Fund VI. Each of Noubar B. Afeyan, Ph.D. and a trust for the benefit of Dr. Afeyan's children received 12,853 shares through Flagship Fund VI GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F9: Shares held by Flagship Fund VI GP. Flagship Pioneering is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,734,994 |
Reported balance
Holding disclosure · report date 2020-11-23 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,734,994 F10: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 376,018 |
Reported balance
Holding disclosure · report date 2020-11-23 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 376,018 F11: Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 23, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 3,587,820 shares and 642,180 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 837,782 shares and 128,452 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. received 335,171 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering and as a manager of Flagship Fund IV GP.
F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On November 23, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") distributed to its limited partners, pro rata and without consideration, 1,186,310 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan Ph.D. is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: On November 23, 2020, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 1,481,481 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed to its members, pro rata and without consideration, the 43,154 shares it received from Flagship Fund VI. Each of Noubar B. Afeyan, Ph.D. and a trust for the benefit of Dr. Afeyan's children received 12,853 shares through Flagship Fund VI GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F8: Shares held by Flagship Fund VI. Flagship Fund VI GP is the general partner of Flagship Fund VI. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Fund VI GP. Flagship Pioneering is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose.
Syros Pharmaceuticals, Inc.
Report date August 17, 2017 · Filed August 21, 2017
Jointly reported with Flagship Ventures Fund IV-Rx, L.P., Flagship VentureLabs IV, LLC, Flagship Ventures Fund IV General Partner LLC, Afeyan Noubar, Kania Edwin
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,378,663 |
Reported balance
After 2017-08-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-08-17 · Other · Disposed 1,295,997 · Balance 2,378,663 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution. F2: Held by Flagship IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 612,442 |
Reported balance
After 2017-08-17 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2017-08-17 · Other · Disposed 306,222 · Balance 612,442 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution. F3: Held by Flagship IV-Rx. Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2017-08-17 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2017-08-17 · Other · Disposed 54,293 · Balance 0 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution. F4: Held by Flagship IV LLC. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV LLC. Each of the filing persons other than Flagship IV LLC disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 213,332 |
Reported balance
Holding disclosure · report date 2017-08-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 213,332 F5: Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship IV is the manager of VentureLabs IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,527 |
Reported balance
Holding disclosure · report date 2017-08-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 24,527 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution. F6: Held by Noubar B. Afeyan, Ph.D. Each of the filing persons other than Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,527 |
Reported balance
Holding disclosure · report date 2017-08-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 24,527 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution. F7: Held by Edwin M. Kania, Jr. Each of the filing persons other than Edwin M. Kania, Jr. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution.
F2: Held by Flagship IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F3: Held by Flagship IV-Rx. Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F4: Held by Flagship IV LLC. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV LLC. Each of the filing persons other than Flagship IV LLC disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F5: Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship IV is the manager of VentureLabs IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F6: Held by Noubar B. Afeyan, Ph.D. Each of the filing persons other than Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F7: Held by Edwin M. Kania, Jr. Each of the filing persons other than Edwin M. Kania, Jr. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Carisma Therapeutics Inc.
Report date September 22, 2016 · Filed September 26, 2016
Jointly reported with Flagship Ventures Fund 2007, L.P., Flagship Ventures Fund IV-Rx, L.P., Flagship Ventures 2007 General Partner LLC, Flagship Ventures Fund IV General Partner LLC, Afeyan Noubar, Kania Edwin
Section 16 reporting ended · disclosed 2016-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 668,912 |
Reported balance
After 2016-09-22 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2016-09-22 · Sale · Disposed 112,731 · Balance 668,912 F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 167,288 |
Reported balance
After 2016-09-22 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2016-09-22 · Sale · Disposed 28,163 · Balance 167,288 F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 480,545 |
Reported balance
After 2016-09-22 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2016-09-22 · Sale · Disposed 188,367 · Balance 480,545 F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 120,198 |
Reported balance
After 2016-09-22 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2016-09-22 · Sale · Disposed 47,090 · Balance 120,198 F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 468,063 |
Reported balance
After 2016-09-23 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2016-09-23 · Sale · Disposed 12,482 · Balance 468,063 F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 117,080 |
Reported balance
After 2016-09-23 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2016-09-23 · Sale · Disposed 3,118 · Balance 117,080 F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 426,885 |
Reported balance
After 2016-09-23 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2016-09-23 · Sale · Disposed 41,178 · Balance 426,885 F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 106,787 |
Reported balance
After 2016-09-23 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2016-09-23 · Sale · Disposed 10,293 · Balance 106,787 F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,833,802 |
Reported balance
Holding disclosure · report date 2016-09-22 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 1,833,802 F3: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
TransMedics Group, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures 2007 General Partner LLC, Flagship Ventures Fund 2007, L.P., Afeyan Noubar
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-10-29 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-10-29 · Other · Disposed 1,469,173 · Balance 0 F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is a manager of Flagship Fund IV GP and, for purposes of Flagship Fund IV's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-10-29 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2019-10-29 · Other · Disposed 1,061,102 · Balance 0 F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4: Shares held by Flagship Fund 2007. Flagship Fund 2007 GP is the general partner of Flagship Fund 2007. Dr. Afeyan is a manager of Flagship Fund 2007 GP and, for purposes of Flagship Fund 2007's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-10-29 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2019-10-29 · Other · Disposed 61,537 · Balance 0 F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F5: Held by Flagship Fund IV GP. Each of the filing persons other than Flagship Fund IV GP disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-10-29 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2019-10-29 · Other · Disposed 248,379 · Balance 0 F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F6: Held by Flagship Fund 2007 GP. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 120,595 |
Reported balance
Holding disclosure · report date 2019-10-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 120,595 F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F7: Held by Dr. Afeyan. Each of the filing persons other than Dr. Afeyan disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is a manager of Flagship Fund IV GP and, for purposes of Flagship Fund IV's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein..
F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F4: Shares held by Flagship Fund 2007. Flagship Fund 2007 GP is the general partner of Flagship Fund 2007. Dr. Afeyan is a manager of Flagship Fund 2007 GP and, for purposes of Flagship Fund 2007's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.
F5: Held by Flagship Fund IV GP. Each of the filing persons other than Flagship Fund IV GP disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.
F6: Held by Flagship Fund 2007 GP. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.
F7: Held by Dr. Afeyan. Each of the filing persons other than Dr. Afeyan disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 23,199 | $67.15 | $1,557,822.13 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 8 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,515,027 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 42,540 | $65.77 | $2,797,689.89 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 7 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,538,226 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.435 to $66.425, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,933 | $72.44 | $140,017.05 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 6 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,406,399 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.22 to $72.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 13,408 | $71.51 | $958,861.05 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,408,332 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 20,492 | $70.46 | $1,443,792.55 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,421,740 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 39,082 | $68.81 | $2,689,404.38 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,442,232 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.50 to $69.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 121,771 | $67.15 | $8,176,971.36 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,481,314 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 223,314 | $65.77 | $14,686,490.86 |
DisclosureSEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,603,085 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.435 to $66.425, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,900,000 | $4.75 | $9,025,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,886,023 F3 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 380,000 | $4.75 | $1,805,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,056,752 F2 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,520,000 | $4.75 | $7,220,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,808,780 F1 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:12 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 2,281,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013020 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:12 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 1,610,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013020 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,580,766 F1 · kind: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:12 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 8,390,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013020 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,826,399 F1 · kind: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 11, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 8,390,000 shares and 1,610,000 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,959,136 shares and 322,043 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 790,980 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. ("Pioneering") and as a manager of Flagship Fund IV GP. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 38,366 | $18.65 | $715,710.06 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 9 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,190,766 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 199,935 | $18.65 | $3,729,747.44 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 8 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,216,399 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc. ("Pioneering"), he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,092 | $18.96 | $77,578.59 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 7 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,229,132 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 21,325 | $18.96 | $404,292.15 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 6 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,416,334 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc. ("Pioneering"), he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 27,714 | $18.99 | $526,408.03 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,233,224 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 144,423 | $18.99 | $2,743,199.35 |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,437,659 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc. ("Pioneering"), he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 1,735,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Pioneering, he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 1,207,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,260,938 F1 · kind: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 00:38 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 6,292,342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028975 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,582,082 F1 · kind: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc. ("Pioneering"), he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 23:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherCommon Stock | 248,379 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026439 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · price: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · balance_after: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F6 · ownership.nature: Held by Flagship Fund 2007 GP. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 23:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherCommon Stock | 61,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026439 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · balance_after: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F5 · ownership.nature: Held by Flagship Fund IV GP. Each of the filing persons other than Flagship Fund IV GP disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 23:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherCommon Stock | 1,061,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026439 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · price: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by Flagship Fund 2007. Flagship Fund 2007 GP is the general partner of Flagship Fund 2007. Dr. Afeyan is a manager of Flagship Fund 2007 GP and, for purposes of Flagship Fund 2007's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 23:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherCommon Stock | 1,469,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026439 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is a manager of Flagship Fund IV GP and, for purposes of Flagship Fund IV's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 895,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 25 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 486,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 89,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 24 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 48,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 358,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 23 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 194,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 151,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 22 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 82,324 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 617,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 21 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 335,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 222,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 20 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 120,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 1,005,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 19 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 545,826 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 928,074 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 18 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 503,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 386,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 17 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 209,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries A Preferred Stock · Derivative | 4,153,847 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 16 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,255,074 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries A Preferred Stock · Derivative | 1,384,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 15 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 751,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 500,000 | $20.00 | $10,000,000.00 |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 14 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 986,023 F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 486,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 13 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 486,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 48,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 12 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 676,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 194,409 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 11 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,288,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 82,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 10 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 628,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 335,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 9 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,094,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 120,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 8 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,761,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 545,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 7 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 545,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 503,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 6 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,758,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 209,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,640,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 2,255,074 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,255,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 751,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,430,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.